Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.
Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J, Huang H, Qin J. Wang H, et al. Among authors: zhang m, zhang g, zhang w. Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9. doi: 10.1016/j.ccell.2023.05.016. Epub 2023 Jun 22. Cancer Cell. 2023. PMID: 37352863
Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to chemotherapy in acute myeloid leukemia.
Jin P, Wang X, Jin Q, Zhang Y, Shen J, Jiang G, Zhu H, Zhao M, Wang D, Li Z, Zhou Y, Li W, Zhang W, Liu Y, Wang S, Jin W, Cao Y, Sheng G, Dong F, Wu S, Li X, Jin Z, He M, Liu X, Chen L, Zhang Y, Wang K, Li J. Jin P, et al. Among authors: zhang w, zhang y. Cancer Res. 2024 Feb 28. doi: 10.1158/0008-5472.CAN-23-2543. Online ahead of print. Cancer Res. 2024. PMID: 38417135
Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Zheng L, et al. Among authors: zhang w, zhang x. Front Immunol. 2023 Jan 26;14:1094378. doi: 10.3389/fimmu.2023.1094378. eCollection 2023. Front Immunol. 2023. PMID: 36776882 Free PMC article.
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).
Zhang B, Zhong H, Shi C, Gao Z, Zhong R, Gu A, Wang W, Chu T, Xiong L, Zhang W, Wang H, Zhang X, Han B. Zhang B, et al. Among authors: zhang w, zhang x. Clin Respir J. 2023 Dec;17(12):1361-1367. doi: 10.1111/crj.13715. Epub 2023 Nov 10. Clin Respir J. 2023. PMID: 37947242 Free PMC article. Clinical Trial.
82,038 results
You have reached the last available page of results. Please see the User Guide for more information.